Physician profile

Asif Imam

Allergy · Riverside, CA

NPI 1225169345

$143.59

in general payments reported to CMS, 2019-2025

5 companies · $43.25 in 2025

The $43.25 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$43.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $61.95 2019-2020
Pfizer INC. $28.84 2025
Optinose US, INC. $20.47 2019
Biocryst US Sales Co., LLC $17.92 2022
Genzyme Corporation $14.41 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Asif Imam

$143.59

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $43.25 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).

https://glasscript.com/doctor/1138519/asif-imam

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.